However, studies in other cancers known to be impacted by EGFR alterations, particularly colon cancers and non-small cell lung carcinoma of the lung, have shown clinical indication for EGFR targeted therapy even in cases where all tumor cells do not express the mutation [28]. This evidence concerns the gene EGFR and neoplasm.